Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,393 result(s) found. Displaying page 1,041 of 2,220.
    «« First « Previous 1037  1038  1039  1040  1041  1042  1043  1044  1045  Next» Last»»
    EudraCT Number: 2013-000944-25 Sponsor Protocol Number: CAIN457F2302E1 Start Date*: 2013-08-02
    Sponsor Name:Novartis Farma S.p.A.
    Full Title: A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005366-35 Sponsor Protocol Number: 10-PN-PD-DIT-085 Start Date*: 2013-02-11
    Sponsor Name:BIOVOMED
    Full Title: Evaluation of the immunogenicity and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate v...
    Medical condition: To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in sub...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019984-12 Sponsor Protocol Number: AMNCH-TCD-CHG-1-2010 Start Date*: 2010-07-21
    Sponsor Name:Adelaide & Meath Hospital, incorporating The National Children's Hospital
    Full Title: A multicentre randomised trial comparing the effects of 2% chlorhexidine gluconate in 70% isopropyl alcohol as a skin, exit site and catheter hub cleansing agent versus other forms of chlorhexidine...
    Medical condition: Prevention of central venous catheter-related infections in haemodialysis patients. This trial will evaluate the effectiveness of 2% chlorhexidine gluconate in 70%isopropyl alcohol as a skin, exit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000301-23 Sponsor Protocol Number: MK-3102-027 Start Date*: 2013-08-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Ina...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Prematurely Ended) AT (Completed) BE (Prematurely Ended) SK (Completed) ES (Completed) DE (Completed) EE (Prematurely Ended) BG (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002903-16 Sponsor Protocol Number: 2197944/201 Start Date*: 2013-04-08
    Sponsor Name:Convergence Pharmaceuticals Ltd
    Full Title: A randomised, double-blind, crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in patients with post-herpetic neuralgia
    Medical condition: Post-herpetic Neuralgia
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2007-005026-76 Sponsor Protocol Number: Anne Pesonen Start Date*: 2007-11-06
    Sponsor Name:Anne Pesonen
    Full Title: Vähentääkö pregabaliini opioidikipulääkityksen tarvetta, postoperatiivista sekavuutta ja kroonisen kivun esiintyvyyttä sydänleikkauksen jälkeen iäkkäillä potilailla?
    Medical condition: Tutkittavat potilaat ovat yli 75-vuotiaita elektiivisen ohitusleikkaukseen tai aorttaläppäleikkaukseen tulevia potilaita.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011099 Coronary disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005013-38 Sponsor Protocol Number: mz01 Start Date*: 2013-02-21
    Sponsor Name:
    Full Title: Effect of GLP-1 on microvascular function in patients with type 2 diabetes
    Medical condition: Microvessel angina is a result of myocardial ischemia from insufficient myocardial perfusion secondary to microvessel dysfunction. Diseased arteries may appear angiographically normal but are dysfu...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004074-28 Sponsor Protocol Number: UKHEP001 Start Date*: 2012-07-20
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicenter, randomized, safety and preliminary efficacy study of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patients
    Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10021601 Inborn error of metabolism NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010966-47 Sponsor Protocol Number: NeSSy_200901 Start Date*: 2010-01-13
    Sponsor Name:Universität Bremen
    Full Title: Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004188-38 Sponsor Protocol Number: DISF1 Start Date*: 2012-10-30
    Sponsor Name:UNIVERSITA' CAMPUS BIOMEDICO
    Full Title: Prospective randomized study FOR THE ASSESSMENT OF EFFECTS OF DIFFERENT Statins ON ENDOTHELIAL FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE
    Medical condition: PATIENTS WITH CORONARY ARTERY DISEASE
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001779-35 Sponsor Protocol Number: 4 Start Date*: 2013-02-15
    Sponsor Name:University of Southampton
    Full Title: The effects of pregabalin augmentation of antidepressant drug on neuro-cognitive functioning in patients with generalized anxiety disorder
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002249-11 Sponsor Protocol Number: BLQ-01-003-04 Start Date*: 2004-09-20
    Sponsor Name:BAUSCH&LOMB - IOM S.P.A.
    Full Title: Double blind, randomized, multicenter, placebo-controlled, parallel-group design clinical trial of the efficacy and tolerability of cloriclomene hydrochloride capsules 100 mg TID in diabetic patien...
    Medical condition: Mild to moderate non-proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000056-18 Sponsor Protocol Number: BTT-gpASIT007 Start Date*: 2013-07-15
    Sponsor Name:BioTech Tools S.A.
    Full Title: Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.
    Medical condition: Treatment of seasonal grass pollen rhinoconjunctivitis.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004870 10019170 Hay fever LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003494-26 Sponsor Protocol Number: Florence-PROTEST Start Date*: 2012-10-26
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: EVALUATION OF THE EFFECT OF TESTOSTERONE REPLACEMENT THERAPY ON PROSTATIC INFLAMMATION AND LOWER URINARY TRACT SYMPTOMS IN HYPOGONADAL SUBJECTS
    Medical condition: metabolic syndrome and BPH patients who will undergo simple prostatectomy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10004447 Benign prostatic hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004356-39 Sponsor Protocol Number: GIMEMAAML19(EORTC06031) Start Date*: 2005-05-16
    Sponsor Name:E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
    Full Title: Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III tr...
    Medical condition: Elderly patients (61-75 years not eligible for intensive chemotherapy;age > 75 years), with previously untreated, primary or secondary (no after other myeloproliferative diseases) AML (except M3).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001012-41 Sponsor Protocol Number: ML18523 Start Date*: 2005-11-29
    Sponsor Name:ROCHE
    Full Title: Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal Cancer
    Medical condition: Patients with inoperable locally advanced or metastatic colorectal cancer, who have not previosly received systemic treatment for metastatic disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000822-38 Sponsor Protocol Number: COSTANT Start Date*: 2008-06-12
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, RANDOMIZED, OPEN LABEL BLINDED END POINT (PROBE), CROSS-OVER STUDY TO COMPARE THE EFFECTS OF TELMISARTAN AND LOSARTAN ON METABOLIC PROFILE OF RENAL TRANSPLANT PATIENTS
    Medical condition: kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000336-25 Sponsor Protocol Number: ML18675 Start Date*: 2005-04-12
    Sponsor Name:ROCHE
    Full Title: Longitudinal analysis of HBV-specific T cell responses in patients with HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon alfa-2a (40 KD) (PEGASYS, Ro 25-8310). Immuno...
    Medical condition: chronic hepatitis B, HBeAg-negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024621-20 Sponsor Protocol Number: IGR2010/1715 Start Date*: 2013-03-26
    Sponsor Name:Institut Gustave Roussy
    Full Title: First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma
    Medical condition: Diagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in liver, bones, lungs and or lymph nodes, combined with at least one of two further confirmatory diagnoses: 1. diagno...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033792 Paraganglion neoplasm NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018119-14 Sponsor Protocol Number: A091758 Start Date*: 2010-07-23
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Huntington's Disease Rilmenidine Safety Trial
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1037  1038  1039  1040  1041  1042  1043  1044  1045  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 09 04:00:41 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA